A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection by Adiwijaya, Bambang S. et al.
A Viral Dynamic Model for Treatment Regimens with
Direct-acting Antivirals for Chronic Hepatitis C Infection
Bambang S. Adiwijaya
1*, Tara L. Kieffer
1, Joshua Henshaw
1, Karen Eisenhauer
1, Holly Kimko
2, John J.
Alam
1, Robert S. Kauffman
1, Varun Garg
1
1Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America, 2Johnson & Johnson Pharmaceutical Research and Development, LLC,
Raritan, New Jersey, United States of America
Abstract
We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to
a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/
ribavirin (PR) in patients with genotype 1 chronic hepatitis C (CHC). This model, which was parameterized with on-treatment
data from early phase clinical studies in treatment-naı ¨ve patients, prospectively predicted sustained virologic response (SVR)
rates that were comparable to observed rates in subsequent clinical trials of regimens with different treatment durations in
treatment-naı ¨ve and treatment-experienced populations. The model explains the clinically-observed responses, taking into
account the IC50, fitness, and prevalence prior to treatment of viral resistant variants and patient diversity in treatment
responses, which result in different eradication times of each variant. The proposed model provides a framework to
optimize treatment strategies and to integrate multifaceted mechanistic information and give insight into novel CHC
treatments that include direct-acting antiviral agents.
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Introduction
Chronic hepatitis C (CHC) affects approximately 180 million
people worldwide and is a frequent cause of increased risk for
hepatic fibrosis, cirrhosis, hepatic failure, and hepatocellular
carcinoma [1,2,3,4]. The treatment objective for CHC is SVR,
or viral eradication, which is considered to be a virologic cure of
the infection. The previous treatment for patients with genotype 1
CHC, 48 weeks of therapy with PR (PR48); results in SVR for
42%–50% of treatment-naı ¨ve patients [5,6]. In clinical trials, a
combination therapy of telaprevir and PR treatment (TPR)
achieved potent antiviral activity and higher SVR rates compared
to treatment with PR alone [7,8,9,10,11,12,13].
As a consequence of its high replication rate and its error-prone
polymerase, the HCV population in a patient exists as quasis-
pecies. At the start of treatment with direct-acting antivirals such
as telaprevir, the HCV population must be considered as a mixed
population, consisting predominantly of wild-type HCV (WT) and
a small population of HCV variants with varying levels of
resistance to telaprevir. The resistant variants generally exist at a
lower frequency than WT prior to the start of treatment [14]
because they are less fit (have lower replicative capacity)
[15,16,17,18,19]. Variants with lower-level resistance (3 to 25-
fold increase in telaprevir IC50 in vitro: V36A, V36M, R155K,
R155T, T54A, A156S) have higher fitness than variants with
higher-level resistance (25-fold increase in telaprevir IC50 in vitro:
A156T, A156V, V36M/R155K) [18]. These variants retain
sensitivity to PR treatment in vitro [20] and in patients
[16,21,22]. WT virus was eliminated more rapidly in the presence
of telaprevir than with interferon-based regimens alone in clinical
trials [23,24].
The treatment duration required to achieve SVR is based on
the time to eradicate all HCV, including WT and all variants. For
PR treatment, models of viral dynamics have successfully
predicted SVR rates by calculating the percentage of patients
whose on-treatment HCV RNA levels reach the viral eradication
limit [25,26,27]. For TPR treatment, because of the presence of
multiple variants in the quasispecies, the time when the level of
each variant within a patient reaches the viral eradication limit
may vary depending on the variant’s fitness and resistance, and
individual patient responses to treatment. The importance of these
different eradication times to treatment strategies has not been
elucidated.
Here, we describe a viral dynamic model of response to TPR
treatment. The model incorporates the presence of viral variants of
differing degrees of resistance and fitness, and the diversity in
patient responses to treatment. The viral dynamic model was
improved from the previously published model [18], with 2 novel
features: 1) the model integrated TPR pharmacokinetics into viral
dynamics, and 2) viral dynamic parameters were estimated using a
population-approach method. The model was developed using in
vitro and clinical data in early studies obtained from 28 patients
treated with 2 weeks of telaprevir monotherapy and 478
treatment-naı ¨ve patients treated with PR and TPR regimens.
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patients. Eradication of each viral variant was simulated as a
discrete event occurring at variable times during treatment: when
eradicated, variants were assumed to stop replicating. If eradica-
tion of all viral variants within a simulated patient was achieved,
the patient was deemed to have reached SVR.
Results
Model development
Model parameters were estimated from HCV RNA and drug
concentration data from 478 patients who participated in early
phase clinical studies (study regimens are described in Supple-
mentary Table S1). The goodness-of-fit plot was provided in
Supplementary Figure S1 and examples of fits in representative
patients were provided in Supplementary Figure S2. The
estimated parameters were provided in Supplementary Table
S2. The estimated replicative fitness among all the variants
(Figure 1) showed that the R155K variant has the highest fitness
(with estimated fitness of about 50% of WT fitness), and the
A156T variant has the lowest fitness (with estimated fitness of
about 10% of WT fitness). Some lower-level telaprevir resistant
variants (R155K, V36M, and V36A) had higher fitness than the
higher-level telaprevir resistant variants (V36M/R155K, A156T).
The other lower-level telaprevir resistant variants (A156S, R155T,
and T54A) had lower fitness than the higher-level telaprevir
resistant variants.
The individual contributions of telaprevir and PR to antiviral
blockage and infected-cell clearance rates estimated from treat-
ment-naı ¨ve population are provided in Table 1. Telaprevir
contribution to production blockage ranged from 22.512log10
to 22.272log10 for WT and lower-level telaprevir resistant
variants and 20.012log10 to 0.002log10 for higher-level telapre-
vir resistant variants, while PR treatment contributed
21.092log10 for all variants. Compared to WT, lower-level
telaprevir resistant variants have similar median blockages but
reduced blockage in the extreme (95
th percentile), which occurred
in patients with lower telaprevir concentrations. Infected-cell
elimination rates were higher for WT and lower-level telaprevir
resistant variants (0.62 d
21) than for higher-level telaprevir
resistant variants (0.29 d
21). The higher elimination rates were
mainly driven by higher antiviral blockage against WT and lower-
level telaprevir resistant variants by telaprevir than by PR. These
results suggest that the primary role of telaprevir is to block viral
replication of WT and lower-level telaprevir resistant variants, and
the primary role of PR is to block viral replication of higher-level
telaprevir resistant variants.
Model evaluation
The model prediction capability was validated by comparing
predicted and observed SVR rates in study regimens in which on-
treatment data were used to estimate the model parameters (478
patients) and in which the model was used strictly in prediction
mode (2380 patients, Supplementary Table S1). Predicted SVR
rates were generated based on these inputs: (a) simulated drug
concentrations and HCV RNA dynamics using parameter values
re-sampled from the estimates; (b) the actual number of patients
treated; (c) the number of patients who prematurely discontinued
treatment; (d) the number of patients who failed to reach SVR
because of other reasons (lost to follow-up, noncompliance, and
withdrawal of consent); (e) the timing of treatment discontinua-
tions; and (f) the distribution of HCV genotype (1a and 1b) for
each regimen/patient population.
Figure 2 shows the correspondence between observed and
predicted SVR rates. In the early studies in which the on-
treatment data were used to develop the model, all observed SVR
rates were within the 90% confidence intervals (CIs) of the
predicted rates. In subsequent studies, observed SVR rates were
also consistent with predicted rates. In the subsequent Phase 2
studies, the majority of the observed SVR rates (13/14 treatment
groups) were within the 90% CI bounds of the predicted rates;
the other group had a rate within 3% of the nearest 90% CI
bounds. In the Phase 3 treatment-naı ¨ve Studies ADVANCE and
ILLUMINATE, the observed rates were within the 90% CI
bounds in 4/5 groups; the other group had an observed rate that
was 1% of the nearest CI bounds. In the Phase 3 treatment-
experienced Study REALIZE, the observed SVR rates were all
lower (by up to 7%) than the 90% CI lower bounds of the
predicted rates. The discrepancy was greatest in the prior PR48-
nonresponder population. In all regimens in this study, observed
SVR rates were lower than predicted rates; therefore, the
comparison of rates among regimens within the study is
comparable between observed and predicted rates.
Despite being trained only for the treatment-naı ¨ve population,
the model produced consistently predictive results even for
different patient populations such as prior PR48-nonresponders
and prior PR48-relapsers. The predicted SVR rates by prior PR48
responses were calculated from a subset of simulated treatment-
naı ¨ve patients by classifying these patients based on their simulated
HCV RNA dynamics in response to PR48 treatment, using the
standard definition of PR responsiveness: prior PR48-SVR, if
patients would reach SVR with PR48 treatment; prior PR48-
relapser, if patients have undetectable HCV RNA at the end of
PR48 treatment but not reached SVR; prior PR48-partial
responder, if patients have more than 2-log10 HCV RNA decline
at week 12 but detectable HCV RNA throughout PR48 treatment,
prior PR48-null responder, if patients have less than 2-log10 HCV
RNA decline at week 12 during PR treatment. Using the
assumption that each subgroup of prior PR responses was a
narrower subset of the diverse PR responsiveness of treatment-
naı ¨ve population, the model was able to predict the observed
Author Summary
Hepatitis C virus chronically infects approximately 180
million people worldwide. The treatment aim for patients
chronically infected with hepatitis C is viral eradication or
sustained viral response (SVR). Historical standard of care
for HCV treatment was peginterferon-alfa and ribavirin.
Recently, approved HCV protease inhibitors, in combina-
tion with peginterferon-alfa and ribavirin, have demon-
strated higher SVR rates compared to peginterferon-alfa
and ribavirin alone. As members of a novel class of
compounds directly targeting hepatitis C virus, HCV
protease inhibitors have different mechanisms of actions
and are affected by resistance and fitness of HCV variants.
The significance of these different mechanisms of action,
and the interplays between resistance and viral fitness to
the treatment outcome has not been elucidated. Here, we
developed and validated an integrative, mechanistic
model of viral dynamics in response to a combination
regimen including telaprevir, peginterferon-alfa, and riba-
virin. The model was developed from early studies in 478
treatment-naı ¨ve patients and its SVR rate predictions were
verified in 2380 patients in subsequent studies. These
results provide an example of the use of mechanistic
information to the development of viral dynamic model
that has been useful in the design of optimal treatment
regimens.
A Model of Direct-acting Antiviral Treatment for HCV
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doi:10.1371/journal.pcbi.1002339.g001
Table 1. Contribution of telaprevir and PR treatment to the antiviral blockage and infected-cell clearance rates in treatment-naı ¨ve
patient population.
Variant Name
Level of
resistance Antiviral blockage log10(1- e) infected-cell clearance d (d
21)
PegIFN/RBV telaprevir
Median 5
th%9 5
th% Median 5
th%9 5
th% Median 5
th%9 5
th%
WT None 21.09 21.28 20.76 22.27 22.68 21.69 0.62 0.36 1.42
R155K Lower 21.09 21.28 20.76 22.51 23.40 21.28 0.65 0.36 1.54
V36A Lower 21.09 21.28 20.76 22.39 23.25 21.19 0.65 0.36 1.49
A156T Higher 21.09 21.28 20.76 20.01 20.02 0.00 0.29 0.24 0.36
V36M/R155K Higher 21.09 21.28 20.76 0.00 20.01 0.00 0.29 0.24 0.36
doi:10.1371/journal.pcbi.1002339.t001
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prior PR48-nonresponders compared to rates in treatment-naı ¨ve
patients.
Viral eradication is dependent on antiviral inhibition,
fitness and resistance of variant populations, and patient
diversity in IFN responsiveness
To examine how viral eradication is affected by variant fitness,
resistance, antiviral inhibition of each drug in the combination
regimen, and patients’ diversity in responses to treatment, simula-
tions were performed for patients with 3 levels of PR responsiveness
treated with 12 weeks of telaprevir in combination with 48 weeks of
PR (T12PR48, Figure 3): 1) typical patient who would achieve SVR
if treated with PR48 (left panel), 2) typical prior PR48-relapser
(middle panel), and 3) typical prior PR48-null-responder (right
panel). Simulated patients were assumed to have subtype 1a or 1b
infection to provide a representative illustration. These simulations
illustrate only representative examples with median responses, as
thereisvariablePRresponsivenessevenwithineachrespectivegroup
of prior PR response (the predicted SVR rates by groups of prior PR
responses are provided elsewhere [28]). Patients in each HCV
subtype were assumed to have the same set of major variants: for
subtype 1a: WT, R155K, V36M/R155K, and A156T; for subtype
1b: WT, V36A, A156T; variants with intermediate fitness or
resistancewerenot included(see methods).The PRresponsivenessof
the first 2 simulated patients with subtype 1a succeeded in
eliminating all variants, but that of the last patient failed to eliminate
the higher-level telaprevir resistant variant V36M/R155K. Both
WT and the lower-level variant R155K were eliminated by about 6
weeks of telaprevir treatment in these 3 patients; however, the
Figure 2. Model verification: Comparison between observed and predicted SVR rates. Notes: Population: failure, patients who were
previously treated with PR48 and did not reach SVR (overall) ; rel, patients who relapsed in previous PR48 treatment; nr, patients who never had
undetectable HCV RNA during previous PR48 treatment (null and partial responders). The control group (PR48) from PROVE3 was not added because
by definition they were failures to PR (predicted SVR rate was zero). Some bounds are overlapping and therefore are not visible in the figure.
Assumptions: The predictions of Study PROVE3 and REALIZE by prior PR responses (overall prior PR48-failure, prior PR48-relapsers, prior PR48-
nonresponders) were obtained from a subset of simulated treatment-naı ¨ve patients based on HCV RNA dynamic criteria provided in the methods
section.
doi:10.1371/journal.pcbi.1002339.g002
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nated only in patients with better PR responsiveness (the first 2
simulated patients). In contrast,the 3 simulated patientswith subtype
1b were able to reach eradication because the PR responsiveness of
these patients overcame the relatively poor fitness of A156 variants
(V36M/R155K variants were not present at baseline in the subtype
1b patients).
The simulation above illustrates that the variability in PR
responsiveness affects the time needed to eradicate higher-level
telaprevir resistant variants. For these 3 simulated patients, the
time to eradicate was similar for WT and lower-level telaprevir
resistant variant R155K. However, the time to eradicate higher-
level telaprevir resistant variants differed by PR responsiveness: for
variant A156, eradication times were 8, 11, and 13 weeks for the 3
patients; for variant V36M/R155K, the eradication time was 5
and 8 weeks for the first 2 patients, and was undefined in the last
patient (because this variant was never eradicated). For the
simulated null-responder patient (which as noted above, represents
a median response for the null responder population), the increase
in the level of V36M/R155K resulted in re-generation of R155K
variant after completion of 12-week telaprevir treatment, resulting
in a viral population with R155K-dominant quasispecies at week
48 (because of the higher fitness of R155K compared to V36M/
R155K). However, a telaprevir duration longer than 12 weeks
would also result in virologic failure but with different predom-
inant variant in the quasispecies when failure is detected (V36M/
R155K variant predominant instead of R155K variant predom-
inant).
To examine the contribution of the eradication assumption—
that a variant stops replicating when its level is below the
eradication limit—a simulation was performed with and without
the eradication assumption. In the simulation without eradication,
all variants were allowed to continue replicating even when their
levels were below the eradication limit. The simulations were
performed for simulated patients with 2 levels of PR responsive-
ness treated with T12PR: 1) typical treatment-naı ¨ve patient
(Figure 4 left panels), and 2) typical patient who would not reach
SVR with PR48 treatment (Figure 4 right panels). In the typical
treatment-naı ¨ve patient, the predicted outcomes were the same
with and without the eradication assumption: Week 48 HCV
RNA levels were below the eradication limit. However, for the
patient who failed to reach SVR with PR48 treatment, the
outcomes differed. The dynamics in the first 12 weeks were the
same: WT and lower-level telaprevir resistant variant levels
reached the eradication limit by week 6. With the eradication
assumption, the quasispecies left were residual higher-level
telaprevir resistant variants with reduced fitness that continued
to be eliminated by PR treatment, resulting in a Week 48 HCV
RNA level below the eradiation limit. Without the eradication
assumption, the WT HCV RNA level returned back to the
baseline value around week 24 after the level reached the
eradiation limit during the first 12 weeks of TPR treatment
(telaprevir was only administered in the first 12 weeks). The return
of HCV RNA levels after the completion of 12 weeks of telaprevir
treatment with quasispecies predominately WT is rarely observed
in clinical trials [8,10,29], supporting the eradication assumption.
The predicted treatment outcomes with and without the
eradication assumption for a population of simulated treatment-
naı ¨ve patients completing a T12PR24 regimen are shown in
Figure 5. Virologic outcomes were categorized as virologic failure
at weeks 1–12 when TPR treatment was administered; virologic
failure at Weeks 13–24 when PR treatment was administered;
Figure 3. Simulated viral dynamics in patients treated with TPR, by prior PR48 responses. Notes: The simulations are for typical subtype
1a (top row) or subtype 1b (second row) patients treated with a combination regimen of 12 weeks of telaprevir and 48 weeks of peginterferon alfa-2a
and ribavirin, with PR responsiveness of a typical simulated prior PR48-SVR, prior PR48-relapse, and prior PR48-null responders. The parameters were
obtained from the median of parameter values in the respective category of simulated PR48 treatment. Parameters used in these simulated patients
are provided in Supplementary Table S4.
doi:10.1371/journal.pcbi.1002339.g003
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administered (relapse); and SVR. Comparing simulations with
and without the eradication assumption, the largest difference was
observed for virologic failure between Weeks 13–24: 4.4% with
eradication and 16.5% without eradication. The virologic failure
rate with the eradication assumption is more consistent with rates
observed in clinical trials (see discussion), supporting the
eradication assumption.
Discussion
An integrated model of viral dynamic responses to treatment
with telaprevir and PR has been developed and validated by
comparing predictions against observed outcomes in late-phase
clinical trials. It provides a framework to integrate multi-faceted
information related to this novel CHC regimen, including in vitro
resistance and fitness, pharmacokinetics, viral sequencing, and
viral dynamics. The framework supported decisions pertaining to
treatment strategies and optimizing regimens during clinical
development. The model that was based on data from early-
phase trials was predictive of observed SVR rates in subsequent
studies that were not used in model building.
The model also aided understanding of a novel CHC treatment
regimen consisting of telaprevir and PR. It provided a consolidat-
ed picture of the interplay between the fitness and resistance of
variant populations, antiviral inhibition by telaprevir and by PR
treatment, and patient diversity in PR responsiveness, and
connected these factors to the ultimate treatment outcome of
SVR. The model suggested that the primary role of telaprevir in a
TPR regimen is to eradicate WT and lower-level telaprevir
resistant variants, and the complementary role of PR is to
eradicate higher-level telaprevir resistant variants. Accordingly,
virologic failure during the telaprevir-treatment phase has been
associated predominately with higher-level telaprevir resistant
variants, indicating a failure of PR to inhibit higher-level telaprevir
resistant variants in some patients [9,29]. Modeling results and
analysis of viral populations derived from patients who stopped
treatment prior to viral eradication [28] have led to the working
hypothesis that a successful regimen should have (1) a telaprevir
treatment duration sufficient to eradicate WT and most lower-
level telaprevir resistant variants, and (2) a PR treatment duration
sufficient to eradicate any remaining variants, particularly higher-
level telaprevir resistant variants. Once WT and lower-level
telaprevir resistant variants have been eradicated and higher-level
telaprevir resistant variants are the dominant residual viral
population, telaprevir adds no additional antiviral effect. The
PR duration required to eradicate higher-level telaprevir resistant
variants depends greatly on the PR responsiveness of a given
patient and likely the number of residual higher-level telaprevir
resistant variants. Because higher-level telaprevir resistant variants
pre-exist at lower frequency than WT and have reduced fitness, a
greater percentage of patients can be treated with a shorter
duration of PR treatment in the TPR regimen than in the PR
regimen. The personalization of PR durations for patients treated
with T12PR treatment has been demonstrated in those who
achieved early virologic response in clinical trials [11,12].
Data and modeling analyses suggest different eradication times
for variants with varying fitness and resistance, leading to different
optimal treatment durations of telaprevir and PR treatment.
Modeling analysis showed that a higher percentage of patients
Figure 4. Simulated viral dynamics of typical patients on T12PR48 treatment, with and without eradication assumption. Notes: The
simulations are for a typical genotype 1a patients treated with a combination regimen of 12 weeks of telaprevir and 48 weeks of peginterferon alfa-2a
and ribavirin, with PR responsiveness of a typical simulated treatment-naı ¨ve and a prior PR48-non-SVR patients. The parameters for the typical PR
treatment-experienced patient were obtained from median values in simulated patients who failed to reach eradication with PR48 treatment. The
analyses of sensitivities to the eradication assumption were performed as follows: ‘‘Yes’’, if variants cannot replicate when their levels are below the
eradication limit; ‘‘No’’, if variants can replicate when their levels are below the eradication limit. The limit of eradication was chosen to be 10
25 IU/
mL, or HCV RNA decline of 212 log10 in a typical patient with HCV RNA baseline level of 10
7 IU/mL.
doi:10.1371/journal.pcbi.1002339.g004
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after the completion of 12 weeks of telaprevir treatment if
simulated without viral eradication, a phenomenon that has rarely
been observed in clinical trials: the virologic failure rates after 12-
week of telaprevir treatment in treatment-naı ¨ve patients were 1%
for the T12PR24 arm of Study PROVE2 [8] and 4.4% in the
T12PR24-48 arms of ADVANCE [28,29]. Moreover, the shorter
eradication times of sensitive variants as compared to resistant
variants are also consistent with the observed more rapid
elimination of WT HCV in patients dosed with telaprevir as
compared to those typically observed in PR treatment [23,24].
The model produced consistently predictive results for different
prior PR48-treatment-failure populations despite being trained
only for the treatment-naı ¨ve population. This finding supports the
hypothesis that a treatment-naive population contains several
types of patients with differing PR responsiveness, and suggests
that a model estimated from the treatment-naive population can
be used to predict results for populations with different PR
responsiveness. In the 2 studies in the treatment-experienced
population (Studies PROVE3 and REALIZE), the predicted and
observed SVR rates were generally consistent: comparable SVR
rates in PROVE3 and slightly higher predicted SVR rates
compared to those rates observed in REALIZE. The discrepancy
is greatest in the prior nonresponder population. The discrepancy
in the REALIZE study may arise from a limitation of the model:
that the underlying parameters constituting PR responsiveness
were assumed to be continuously distributed in treatment-naı ¨ve
population, while the actual parameters may be more discrete and
based on other factors such as the IL28B genotypes [30], which
has been reported to produce different viral dynamics in response
to PR treatment [31,32]. Alternatively, the discrepancy may be
attributed to a higher proportion of patients with adverse
prognostic factors for achieving SVR (e.g., advanced liver disease)
enrolled in REALIZE, whereas the predictions were generated
from the dataset that contained treatment-naı ¨ve patients with
fewer of these adverse factors. In the modeling described here,
adverse factors were not formally examined as covariates because
of the limited data available from the early studies.
In summary, the proposed model served as a framework in
integrating information from multiple sources and was useful in
supporting decision-making for the optimization of treatment
strategies during clinical development. The model provided
insights to help design novel treatment regimens of combination
therapy with telaprevir, peginterferon alfa-2a and ribavirin for
CHC treatment, and may be useful for evaluating future CHC
treatment regimens that include direct-acting antiviral agents.
Methods
Ethics statement
The study protocols and informed consent forms were reviewed
and approved by ethics committees or institutional review boards
for each clinical research site before initiation of studies at that site.
Written informed consent was obtained in accordance with the
Declaration of Helsinski.
Data source
The model was developed from HCV RNA and drug
concentration from a total of 478 patients treated with PR and
TPR regimens in early studies of telaprevir. The model was
validated using outcomes from 2380 patients in later studies. The
list of studies is provided in Supplementary Table S1. The study
design, enrollment criteria, and primary results have been
published elsewhere [7,8,9,10,11,12,13,33]. Only quantifiable
HCV RNA data were used in the estimation. Additional
limitations were implemented: 1) for PR regimens, only HCV
RNA data up to time when the first dose modifications of either
peginterferon or ribavirin were used (or end of the treatment) to
evaluate the PR responses with one dose level; and 2) for TPR
regimens, only patients with WT-dominant quasispecies (98% of
Figure 5. Predicted clinical outcome among treatment-naı ¨ve patients who completed T12PR24 treatment, with and without the
eradication assumption. Notes: The simulations are for a simulated treatment-naı ¨ve population, with HCV genotype 1a:1b ratio of 1:1. The
analyses of sensitivities to the eradication assumption were performed as follows: ‘‘Yes’’, if variants cannot replicate when their levels are below
eradication limit; ‘‘No’’, if variants can replicate when their levels are below eradication limit. The simulated clinical outcomes were defined as follows:
Failure at Week 1–12, HCV RNA returns back to detectable levels in the first 12 weeks (during telaprevir treatment); Failure at Week 13–24, HCV RNA
levels return back to detectable level during Weeks 13–24 of therapy (during PR treatment, after completion of 12 weeks of telaprevir treatment);
Relapse, HCV RNA undetectable at the end of treatment, but did not reach eradication; SVR, eradicated prior to the end of treatment. Compared to
the simulated outcomes without the eradication assumption, the simulated outcomes with the eradication assumption better matched the observed
clinical outcomes.
doi:10.1371/journal.pcbi.1002339.g005
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variant dominant quasispecies. While the model can be applied to
the patients with resistant-variant dominant quasispecies, the small
number of patients in this dataset prevented us from making
accurate conclusion regarding the comparability of the fitness of
resistant variants in these patients to those in patients with WT-
dominant quasispecies.
Model structure and estimation
The model structure is given in Equations 1–8, and the
descriptions of symbols are given in Table 2. Drug pharmacoki-
netics were estimated from time-concentration data in early
studies. Telaprevir and peginterferon alfa-2a pharmacokinetics
were described by one-compartmental models and provided in
Equation 8. Ribavirin pharmacokinetics were described by a 3-
compartmental model, with parameters estimated using empirical
Bayesian feedback from published distributions of parameter
estimates [34]. Model-predicted drug concentrations were simu-
lated based on the dosing records and pharmacokinetic model
parameters and were entered into the viral dynamic model.
T
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8
> > > > > > > > > > > > > > <
> > > > > > > > > > > > > > :
ð8Þ
A schematic of the viral dynamic model is provided in Figure 6.
Viral populations were represented as a mixture of quasispecies
with varying fitness and sensitivities to telaprevir. Variant V
represents a virion with characterized amino-acid substitution(s) in
the NS3/4A protease. Variant Vi infects target cells (T) to form V-
infected cells (I) at rate bTV. Each variant competes for the same
target cells T. Target cells T also represent limited ‘‘replication
space’’ shared by all variants; target cell T has a synthesis rate s
and a first-order elimination d. In [18], a model with different
representation of T (which maintain T+I) resulted in comparable
estimates. The maximum target cells were assumed to be 10
11
[35]. Each infected cell (I) produces a population of variants at
production rate pf, with a m-fraction of this production mutating to
produce variant j (V). The mutation rate was assumed to be 1.2
10
24 base
21 cycle
21 [36]. The production rate ratio (f) quantifies
variant replicative fitness in the absence of any drug. Different
production rates (pf ), but the same infection (b) and clearance (c)
rates, are assumed for different variants. This assumption is
consistent with the function of the NS3/4A protease to cleave a
Table 2. Description of symbols used in Equations 1–8.
Symbol Description
(dot above)
a variable
time-derivative of a state variable
T Healthy target cells
s Target cell synthesis rate
d Target cell degradation rate
g Blockage of infection
b Infection rate
Vi or Vj Plasma virion ‘‘i’’ or ‘‘j’’
Ii Variant-i-infected cells
di Variant-i-infected-cell clearance rate
Dd Infected-cell clearance proportionality
constant of drug d
dnodrug Infected-cell clearance in the absence of any drug
p Production rate of wild-type (WT)
mj,i Mutation rates from Vj to Vi
ei Blockage of production
fi Variant-i fitness: production rate relative to WT
c Plasma virion clearance rate
SVRdef HCV RNA limit of eradication
[Concd] Plasma concentration of drug d
(d=telaprevir, Peg-IFN, RBV)
Kd Multiplier of plasma to effective concentrations
for drug d (d=telaprevir, Peg-IFN, RBV)
IC50,i,d IC50 of variant i to drug d (based on
measurement in HCV replicon cells)
h,i,d Hill coefficient of variant i to drug d
(based on measurement in HCV replicon cells)
r Ratio between g and eiP
Ka,d Absorption constant of drug d
Vd Volume of distribution of drug d
Cld Clearance of drug d
Fd Bioavailability of drug d
Dd Dose of drug d
doi:10.1371/journal.pcbi.1002339.t002
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cycle [37]. Each drug (telaprevir, peginterferon alfa-2a, ribavirin)
assumes a dual role in clearing HCV. First, each drug blocks viral
production by a factor (1- e). Telaprevir antiviral blockage ei,T is
constrained to be consistent with in vitro sensitivity assay of variant
i to telaprevir [38,39,40]. Blockage by peginterferon alfa-2a and
ribavirin are assumed to be equal among variants, consistent with
in vitro sensitivity assay. While the antiviral mechanism of
ribavirin (of whether ribavirin blocked viral production or changed
infectious into noninfectious viral strains) remained controversial,
our data were unable to distinguish a model with a simple
production blockage from a model with infectious and noninfec-
tious viral strains [25], and therefore, a simpler model with
production blockage was chosen instead of the alternative model
because the alternative model would need twice as many number
of variants. The blockage factors were calculated as a function of
plasma concentrations of each drug (multiplied by a factor k to
convert plasma to effective concentrations), and the sensitivities of
each variant as measured in HCV replicon cells (represented by
parameters IC50, and hill-power values h). Overall blockage in the
combination regimen assumed additive (in logarithmic scale)
blockages of each drug. The second role of each drug is to enhance
the infected-cell clearance d.W TdWT values were up to 10-times
higher in patients dosed with telaprevir than in patients treated
with interferon-based regimen alone [41,42]. These observations
were represented into the model by assuming that d increased
proportionally with log10(1-e) [18]. The enhanced d may be
attributed to increases in infected-cell clearance or uncovering of
intracellular viral RNA [27]. Consistently, as these mechanisms
may not be specific to direct-acting antivirals, the enhancement
may also be observed for interferon if its effectiveness is high
enough.
Model assumptions and limitations
The HCV variants used in this model was based on the major
variants detected in clinical studies: one major variant with the
highest fitness for each of the resistant groups (lower-level and
higher-level resistance) and the nucleotide changes from WT.
Subtypes 1a and 1b were modeled separately because when
telaprevir was administered in monotherapy, different sets of
resistant variants emerged [15,16]. All patients with the same
subtype were assumed to have the same set of major variants: for
subtype 1a: WT, R155K, V36M/R155K, and A156T/V; for
subtype 1b: WT, V36A, A156T/V. The frequency of these
variants prior to treatment was calculated by assuming a steady-
state condition. The intermediate-resistant variants R155T/I and
other minority variants observed in a few patients were not
included in the model used to generate predictions because of
lack of data to estimate their fitness. Including these variants in
the model was expected to result in only small changes in the
SVR rates, because these variants appeared to be less fit than the
variants used in the model [18]. The parameters related to the
antiviral activity of peginterferon alfa and ribavirin were
correlated because the current training dataset contained data
from regimens where peginterferon and ribavirin were adminis-
tered simultaneously. Because of the data limitation, the
proportionality constant related to the enhanced infected-cell
clearance for ribavirin is assumed to be equal to the constant for
peginterferon.
Calculation of predicted SVR rates
SVR rates were predicted by evaluating simulated HCV RNA
dynamics and entering the observed patient disposition into the
model. The predicted HCV RNA dynamics for treatment-naı ¨ve
patients were generated by simulations, with parameters re-
sampled from the distributions of estimates in Supplementary
Table S2, truncated by lower and upper bounds (bounds were
obtained from the extreme values of the observed individual
estimates). Dosing compliance was assumed to be 100%. Ribavirin
dose modification followed the observed modification in the
training dataset. A simulated patient was considered to achieve
eradication (or SVR) if the overall HCV RNA level by the end of
treatment was below 1 copy in the body [25] (or reached a 12-log
decline from baseline in HCV RNA, assuming a baseline value of
10
7 IU/mL).
Predicted SVR rates for different categories of PR responsive-
ness (SVR with PR48, prior PR48-non-SVR, prior PR48-relapser,
prior PR48-nonresponder, prior PR48-null responder) were
generated by simulating HCV RNA dynamics to PR48 treatment,
and by filtering the responses with the respective PR responsive-
ness criteria. The categories of PR responsiveness followed these
criteria: SVR with PR48, if patient’s viral load reached eradication
by the end treatment; prior PR48-non-SVR, if patient’s viral load
did not reach eradication by the end of treatment; prior PR48-
relapser, if patient’s viral load was undetectable by the end of
treatment but did not reach eradication; prior PR48-nonrespond-
er, if patient’s viral load was always detectable during treatment;
prior PR48-null-responder, if patient’s viral load at week 12
declined ,22log10.
Numerical implementation
Drug concentrations were estimated or simulated using a
Bayesian approach implemented in NONMEM version 6. Viral
dynamic model was implemented in JacobianH software version
4.0 (RES group, Inc., Cambridge, MA).
Supporting Information
Figure S1 Goodness of fit plot of HCV RNA Log10
decline. DV=observed values; IPRED=model-fit values;
IWRES=residual values.
(DOC)
Figure 6. Multi-variant, viral dynamic model of a combination
regimen of telaprevir and PR treatment. Parameters are defined in
Supplementary Table S2 and Supplementary Table S3.
doi:10.1371/journal.pcbi.1002339.g006
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tration of telaprevir and ribavirin is expressed in mg/mL; serum
concentration of Peg-IFN is expressed in ng/mL. Two-step
parameter estimations were performed for each patient: 1)
estimation of PK parameters; and 2) estimation of HCV RNA
dynamic parameters with PK parameters as inputs. For estimation
of PK parameters, the following parameters were estimated from
PK measurements of telaprevir and of Peg-IFN: Ka, Cl, and V;
and these parameters were estimated from PK measurements of
RBV: Ka, Cl, Q3, Q4, V2, V3, V4 [34]. For patients treated with
PR regimen, the following parameters were estimated from
HCVRNA measurements: c, dP, kP, kR, and r. For patients
treated with TPR g1b regimen, the following parameters were
estimated from HCV RNA measurements: c, dT,,dP, kT, kP, kR, r,
fR155K,f A156T,f V36MR155K. For patients treated with TPR g1b
regimen, the following parameters were estimated from HCV
RNA measurements: c, dT,,dP, kT, kP, kR, r,f V36A,f A156T.
(EPS)
Table S1 Source and description of study regimens
used for model estimation and verification.
(DOC)
Table S2 Final parameter estimates of pharmacokinet-
ics and viral dynamics from data obtained in 28 patients
treated with 2 weeks of telaprevir in monotherapy and
in 478 treatment-naı ¨ve patients treated with PR and TPR
regimens. Each parameter assumed lognormal distribution, of
which log10 of mean and variance were provided.
(DOC)
Table S3 Parameters obtained from literature or
assumed. Assumed values have been verified not to change
the conclusions of the results.
(DOC)
Table S4 Parameter values used in Figure 3.
(DOC)
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